MedTrace Logo

Automated Brain Morphometry for Dementia Diagnosis

NCT02286505 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-11-07

No results posted yet for this study

Summary

Early dementia diagnosis improves patient and carer experience, links them to appropriate care and support and enables timely symptomatic treatment. The guidelines of the UK National Institute for Health and Care Excellence recommend brain Magnetic resonance imaging (MRI) to assist with the diagnosis in suspected dementia. Recently, computerised analysis of MRI scans, also known as automated brain morphometry, has shown potential to detect the brain changes characteristic of early dementia, and may therefore be a useful addition to the standard reporting performed by a neuroradiologist. The present pilot study will assess whether adding brain morphometric analysis to the usual diagnostic pathway improve diagnosis in clinical practice as an addition to the existing diagnostic pathway in a memory clinic setting. The main purpose of the study is to compare measures of the clinicians diagnostic confidence in patients with and without brain morphometry.

Conditions

Interventions

DEVICE

Brain Morphometry

Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.

OTHER

Standard radiological assessment

Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.

Sponsors & Collaborators

  • Imperial College London

    collaborator OTHER

  • University of Sussex

    collaborator OTHER

  • IXICO Limited

    collaborator UNKNOWN

  • Cambridge Cognition Ltd

    collaborator INDUSTRY

  • King's College London

    lead OTHER

Principal Investigators

  • Sergi Costafreda-Gonzalez, MD, PhD · King's College London

  • Andrew Simmons, PhD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
51 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02286505 on ClinicalTrials.gov